博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06955 博安生物

未开盘 09-09 16:08:06

2.815

-0.280

-9.05%

最高3.110	最低2.780	成交量497.22万
今开3.110	昨收3.095	日振幅10.66%
总市值17.34亿	流通市值17.34亿	总股本6.16亿
成交额1,456万	换手率0.81%	流通股本6.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06955","market":"HK","secType":"STK","nameCN":"博安生物","latestPrice":2.815,"timestamp":1788941286006,"preClose":3.095,"halted":0,"volume":4972200,"delay":0,"changeRate":-0.09046849757673675,"floatShares":616000000,"shares":616000000,"eps":0.014511830422610318,"marketStatus":"未开盘","change":-0.28,"latestTime":"09-09 16:08:06","open":3.11,"high":3.11,"low":2.78,"amount":14561303,"amplitude":0.106624,"askPrice":2.895,"askSize":1200,"bidPrice":2.815,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-0.1879405972536995,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789003800000},"marketStatusCode":0,"adr":0,"listingDate":1672329600000,"exchange":"SEHK","adjPreClose":3.095,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":0.92287,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06955/wiki","defaultTab":"wiki","newsList":[{"id":"1193382798","title":"博安生物（06955）签署融资租赁补充协议　维持购回价75百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193382798","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193382798?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:35","pubTimestamp":1788960930,"startTime":"0","endTime":"0","summary":"2026年9月9日，山東博安生物技術股份有限公司公告称，公司与兴业金融租赁有限责任公司就2026年8月27日签订的融资租赁协议签署补充协议，明确并确认相关租赁资产的购回价格维持人民币75百万元不变。补充协议确认购回价75百万元系参照该账面值，并综合考虑租赁期内预计折旧及资产可使用状况等因素后确定。公司董事会表示，补充协议在双方公平协商基础上签订，条款公平合理，符合公司及其股东的整体利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105509219","title":"博安生物9月9日回购100万股股份，总涉资约292.20万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105509219","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105509219?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:06","pubTimestamp":1788951970,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司于2026年9月9日发布翌日披露报表，公告当日在香港联交所回购公司股份。此次回购数量为1,000,000股，约占回购前公司已发行股份总数的0.1624%。回购价格区间为每股2.825港元至3.1港元，经成交均价加权后为每股2.922港元，总耗资约292.20万港元。回购后，公司已发行股本变更为614,933,694股，库藏股数增至7,400,000股，合并口径下总股本维持在622,333,694股。此外，本次回购完成后，公司将在2026年10月9日之前暂停任何新股发行或库藏股再出售或转让操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物9月9日回购100万股股份，总涉资约292.20万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666345587","title":"博安生物(06955)9月9日斥资292.2万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666345587","media":"智通财经","labels":["shareholding"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666345587?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:03","pubTimestamp":1788951783,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年9月9日斥资292.2万港元回购100万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物(06955)9月9日斥资292.2万港元回购100万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179066363","title":"博安生物9月8日回购150万股股份，总额约455.37万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179066363","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179066363?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:36","pubTimestamp":1788863767,"startTime":"0","endTime":"0","summary":"2026年9月8日，博安生物在香港联交所场内回购150万股普通股，占当日前已发行股份约0.2429%。本次回购每股价格介乎于2.835港元至3.245港元，合计耗资4,553,729港元，约455.37万港元。公司于2026年6月22日通过了股份回购授权，授权规模为62,233,369股，截至目前已累计回购并持有6,400,000股，占授权总数约1.0284%。公告显示，公司确认本次股份回购已遵守香港联交所证券上市规则及相关法律法规。公告由公司董事姜华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物9月8日回购150万股股份，总额约455.37万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141833562","title":"博安生物9月7日回购170万股股份，涉资约523.73万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141833562","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141833562?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:36","pubTimestamp":1788780976,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司于2026年9月7日发布翌日披露报表，披露公司于同日通过香港联交所场内回购股份170万股。该回购股份数量约占此前已发行股本的0.2746%，每股回购价介乎港币3.23元至港币2.71元，总金额约523.73万港元。本次回购前，博安生物已发行股份为619,133,694股，库藏股为3,200,000股。回购完成后，公司已发行股份减少至617,433,694股，库藏股增至4,900,000股，总股本保持在622,333,694股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物9月7日回购170万股股份，涉资约523.73万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665189319","title":"博安生物(06955)9月7日斥资523.7万港元回购170万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665189319","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665189319?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:32","pubTimestamp":1788780761,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年9月7日斥资523.7万港元回购170万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665962103","title":"港股异动 | 博安生物(06955.HK)一度跌超20%创新低 遭剔除港股通名单 上半年盈转亏约8300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665962103","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665962103?lang=zh_cn&edition=full","pubTime":"2026-09-07 11:46","pubTimestamp":1788752778,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127760494","title":"博安生物9月4日回购120万股，涉资约412.73万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127760494","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127760494?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:06","pubTimestamp":1788523594,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司于2026年9月4日公告，披露了一项于香港联交所场内进行的股份购回交易。公告显示，公司本次回购合共120万股H股，占购回前已发行股份约0.1934%。每股回购价介乎3.35港元至3.49港元，合计涉资约412.73万港元。根据公告，此次回购完成后，公司已发行股份数目由620,333,694股降至619,133,694股，同时其库藏股数目增至3,200,000股。博安生物确认，本次购回行为遵守香港联交所上市规则及相关法律法规。公告由公司董事姜华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物9月4日回购120万股，涉资约412.73万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664133199","title":"博安生物(06955.HK)9月4日斥资约412.73万港元回购120万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664133199","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664133199?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:02","pubTimestamp":1788523370,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188978742","title":"博安生物2026年8月股份变动月报表披露：回购2,000,000股后股本总数维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1188978742","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188978742?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:53","pubTimestamp":1788512037,"startTime":"0","endTime":"0","summary":"2026年9月4日，博安生物发布2026年8月证券变动月报表。报告期为截至2026年8月31日，公司注册股本维持不变，注册股本仍为人民币622,333,694元，股份面值为每股人民币1元。公司于2026年8月28日以每股港币3.7355元价格回购股票2,000,000股，并将该部分股份计为库存股。在库存股方面，本次回购的2,000,000股目前作为库存股份持有，暂未注销。本次月报由公司董事姜华签署。公司将持续关注市场情况，并按照监管要求及时披露后续股本变动信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662292098","title":"博安生物(06955)8月28日斥资747.1万港元回购200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662292098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662292098?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:32","pubTimestamp":1787920350,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年8月28日，该公司斥资747.1万港元回购200万股股份，每股回购价3.625-3.76港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178654746","title":"博安生物8月28日回购200万股，耗资约747.10万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178654746","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178654746?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:57","pubTimestamp":1787918249,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司于2026年8月28日回购股份。据公告披露，本次回购共涉及2,000,000股，约占该公司回购前已发行股本总数的0.3214%。本次于香港联交所场内的回购价格介于每股3.63港元至3.76港元，总耗资7,471,022.00港元，折合约747.10万港元。据公告，回购所涉授权已于2026年6月22日通过，授权回购股份的总数为62,233,369股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规，并已获得董事会正式授权批准。公告由公司董事姜华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博安生物8月28日回购200万股，耗资约747.10万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662089551","title":"博安生物(06955.HK)中期亏损8300万元 同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2662089551","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662089551?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:57","pubTimestamp":1787842621,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨博安生物发布截至2026年6月30日止六个月之中期业绩。集团的收入约为人民币2.33亿元，同比下降40.8%。期内亏损为人民币8300万元，而截至2025年6月30日止六个月为溢利人民币2050万元，每股基本亏损0.13元。集团的研究及开发开支约为人民币9200万元，较截至2025年6月30日止六个月增加约人民币3340万元。　　商业化方面，于2026年1月，集团的60mg地舒单抗注射液(博优倍)已获玻利维亚国家药品和卫生技术局批准上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32350747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662086798","title":"博安生物(06955)：订立融资租赁协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2662086798","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662086798?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:47","pubTimestamp":1787842037,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年8月27日，公司(承租人)与兴业金租订立融资租赁协议，据此，兴业金租将自公司购买租赁资产并将于租赁期内向公司出租该等租赁资产，但可根据融资租赁协议的条款及条件提早终止。租赁资产为兴业金租所租赁的若干机械及设备。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185243426","title":"博安生物2026年上半年营收2.33亿元，净亏损0.83亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185243426","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185243426?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:36","pubTimestamp":1787841389,"startTime":"0","endTime":"0","summary":"本期信息显示，博安生物截至2026年6月30日止六个月实现营收2.33亿元，同比下降40.8%。期内净亏损0.83亿元，上年同期录得利润0.20亿元，主要原因是受政府主导集采政策预期及研发投入增长等因素影响。销售及经销费用1.07亿元，同比下降33.0%，主要与报告期销售收入减少幅度相符；管理费用0.16亿元，同比下降约33.0%，主要系精简措施提升运营效率；研发开支0.92亿元，同比增加57.0%，占总营收约39.4%，显示在创新药管线上持续投入。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"博安生物2026年上半年营收2.33亿元，净亏损0.83亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1187676793","title":"博安生物（06955.HK）签订75百万元融资租赁协议 优化资金结构","url":"https://stock-news.laohu8.com/highlight/detail?id=1187676793","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187676793?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:35","pubTimestamp":1787841337,"startTime":"0","endTime":"0","summary":"2026年8月27日，博安生物公告称，公司已与兴业金融租赁有限责任公司签署融资租赁协议。根据协议，兴业金租将以人民币75.00百万元的价格向博安生物购买若干机械及设备，并在36个月租赁期内回租给博安生物。期间租金按季度分12期支付，租赁总额约为人民币79.85百万元，其中包括租赁本金75.00百万元及按贷款市场报价利率上浮40个基点计息的利息4.85百万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153864545","title":"山东博安生物：兴业金融租赁公司将购回租赁资产","url":"https://stock-news.laohu8.com/highlight/detail?id=1153864545","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153864545?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:35","pubTimestamp":1787841309,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司（06955.HK）宣布，兴业金融租赁有限责任公司将从公司手中购回租赁资产。此举标志着双方在租赁业务上的又一重要合作进展。据悉，该交易涉及具体的资产购回安排，进一步优化公司的资产结构。博安生物作为生物制药领域的创新企业，此次资产处置或为其带来资金流动性支持，助力研发与业务拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141997819","title":"山东博安生物：租赁资产系指兴业金融租赁所持有的相关机械设备","url":"https://stock-news.laohu8.com/highlight/detail?id=1141997819","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141997819?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:35","pubTimestamp":1787841308,"startTime":"0","endTime":"0","summary":"山东博安生物公告，其租赁资产所指，正是兴业金融租赁所出租的部分机械设备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662713154","title":"博安生物(06955)：BA2201(TL1A/IL-23)临床试验申请获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2662713154","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662713154?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:11","pubTimestamp":1787742677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，BA2201的新药临床试验申请已获得中国国家药品监督管理局药品审评中心受理。BA2201有望成为中国首批进入临床阶段的TL1A/IL-23双抗药之一。针对上述临床需求，BA2201同时靶向IL-23和TL1A两条核心致病通路。临床前研究显示，BA2201可高效阻断TL1A与DR3的结合;其IL-23结合端亦保持较强的通路抑制活性。此外，BA2201高浓度皮下制剂具有良好稳定性，为临床给药提供便利性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","LU1223083913.SGD","LU1223082519.USD","CDE","IBBJ","PSYK","06955","XME","SGDM","BK1161","GDXJ","IBBQ","SIL","BK4017","LU1223082196.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185211188","title":"博安生物TL1A/IL-23双特异性抗体BA2201获CDE临床试验申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1185211188","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185211188?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:08","pubTimestamp":1787742481,"startTime":"0","endTime":"0","summary":"博安生物（06955.HK）宣布，其自主研发的TL1A/IL-23双特异性抗体BA2201的临床试验申请（IND）已获得中国国家药品监督管理局药品审评中心（CDE）的正式受理。\n这一关键进展标志着该创新疗法迈入临床开发新阶段。BA2201作为一款靶向TL1A与IL-23的双特异性抗体，有望在自身免疫性疾病治疗领域展现差异化优势。\n博安生物表示，此次IND受理为公司管线推进注入新动力，后续将严格按照监管要求开展相关临床试验工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boan-bio.com","stockEarnings":[{"period":"1week","weight":-0.217},{"period":"1month","weight":-0.4023},{"period":"3month","weight":-0.4148},{"period":"6month","weight":-0.6013},{"period":"1year","weight":-0.7891},{"period":"ytd","weight":-0.6704}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.0255},{"period":"3month","weight":0.0423},{"period":"6month","weight":-0.0075},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东博安生物技术股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事治疗用抗体的开发、生产和商业化，专注于肿瘤学、代谢学、自身免疫学和眼科等治疗领域。该公司主要拥有三个技术平台：全人抗体转基因小鼠及噬菌体展示技术平台、双特异T-cell Engager技术平台、抗体药物偶联（ADC）技术平台。该公司主要在中国国内市场和海外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.161165},{"month":2,"riseRate":0.5,"avgChangeRate":-0.012143},{"month":3,"riseRate":0.25,"avgChangeRate":-0.003652},{"month":4,"riseRate":0.75,"avgChangeRate":0.065191},{"month":5,"riseRate":0.25,"avgChangeRate":-0.057252},{"month":6,"riseRate":0.25,"avgChangeRate":-0.04333},{"month":7,"riseRate":0.75,"avgChangeRate":0.130145},{"month":8,"riseRate":0,"avgChangeRate":-0.130814},{"month":9,"riseRate":0.5,"avgChangeRate":-0.025935},{"month":10,"riseRate":0,"avgChangeRate":-0.109251},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.02386},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.011932}],"exchange":"SEHK","name":"博安生物","nameEN":"BOAN BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博安生物,06955,博安生物股票,博安生物股票老虎,博安生物股票老虎国际,博安生物行情,博安生物股票行情,博安生物股价,博安生物股市,博安生物股票价格,博安生物股票交易,博安生物股票购买,博安生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}